Form 4: Nautilus Biotech Grants Chief Scientist 280,000 Stock Options

Nautilus Biotechnology, Inc. has granted Chief Scientist Parag Mallick 280,000 stock options with a $2.32 exercise price, vesting over four years.

Summary

• Parag Mallick, Chief Scientist, Director, and 10% Owner of Nautilus Biotechnology, Inc. (NAUT), was granted 280,000 stock options.
• The options have an exercise price of $2.32 per share.
• The grant date for these options was March 2, 2026, and they expire on March 2, 2036.
• Vesting is contingent upon Mallick's continuous status as a 'Service Provider' under the Issuer's 2021 Equity Incentive Plan.
• Twenty-five percent (25%) of the shares subject to the option will vest on the one-year anniversary of the Vesting Commencement Date, which is January 1, 2026.
• One thirty-sixth (1/36th) of the remaining shares will vest each month thereafter.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event. While it introduces potential dilution, it primarily signals strong alignment between a key executive's incentives and the company's long-term performance, which is beneficial for corporate governance and strategic execution.

Positives

• The option grant aligns the Chief Scientist's incentives with long-term shareholder value creation.
• It demonstrates continued commitment from a key executive, who is also a Director and 10% Owner, to the company's future success.

Negatives

• The grant of 280,000 options could lead to potential dilution for existing shareholders if exercised, although this is a standard practice for executive compensation.

Risks

• The vesting of the options is subject to Parag Mallick's continuous status as a 'Service Provider,' meaning if his employment or service terminates, unvested options would be forfeited.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the vesting schedule of the granted options, which extends over several years.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like a Chief Scientist is a common practice in the biotechnology industry. It serves to attract, retain, and motivate talent by aligning their financial interests with the long-term performance of the company, especially in a sector where innovation and scientific leadership are critical for success. This particular grant to a Director, 10% Owner, and Chief Scientist underscores the company's reliance on his continued contributions.

Comparison to Industry Standards

• The vesting schedule, with a one-year cliff followed by monthly vesting over three years, is a standard practice in the technology and biotechnology sectors, comparable to grants seen at companies like Illumina or Pacific Biosciences, designed to ensure long-term commitment.
• The exercise price being at or above the market price on the grant date (implied by the lack of a stated discount) is typical for incentive stock options, ensuring the executive benefits only if the stock price appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefits from incentivized management focused on long-term growth.
• Employees: May signal stability and a commitment to retaining key talent, potentially boosting morale.

Next Steps

• The options will begin vesting on January 1, 2027 (one year after the Vesting Commencement Date) for the initial 25% tranche.
• Subsequent vesting will occur monthly thereafter, contingent on continuous service.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (stock option grant) and does not contain information that would fundamentally alter the investment thesis for Nautilus Biotechnology. While it aligns management incentives, it's a standard operational disclosure rather than a catalyst for significant price movement. Investors should continue to hold and monitor broader company performance and industry trends.

Keywords

Nautilus Biotechnology, NAUT, Stock Options, Executive Compensation, SEC Form 4, Insider Transaction, Biotechnology, Equity Incentive Plan, Parag Mallick